Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-03-10
2002-01-29
Wang, Andrew (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S069100, C435S091100, C435S375000, C435S455000, C536S023100, C536S023500, C536S024500
Reexamination Certificate
active
06342356
ABSTRACT:
BACKGROUND OF THE INVENTION
Functional inactivation of genes through the expression of synthetic genetic elements comprising all or a part of the gene to be inactivated is known in the art. At least four mechanisms exist by which expression of such specific genetic elements can result in inactivation of their corresponding gene. These are interference with protein function by polypeptides comprising nonfunctional or partly nonfunctional analogs of the protein to be inhibited or a portion thereof, interference with mRNA translation by complementary anti-sense RNA or DNA, destruction of mRNA by anti-sense RNA coupled with ribozymes, and interference with mRNA by RNA sequences homologous to a portion of the mRNA representing an important regulatory sequence.
Although gene suppression is quite useful for scientific studies of gene function and holds considerable promise for certain applications in disease therapy and genetic modification of plants and animals, current methods for identifying effective synthetic genetic elements (SGEs) are time consuming and arduous. Interference by dominant negative mutant proteins, for example, either requires extensive knowledge about the functional domain structure of the protein so that reasonably promising candidate mutant proteins can be prepared, or necessitates individual preparation and screening of numerous candidate mutant proteins. Antisense RNA and competitive homologous RNA similarly require extensive individual preparation and screening of candidate inhibitory sequences, absent considerable knowledge about important specific sequences within the RNA.
There is, therefore, a need for generalized methods for identifying and isolating SGEs that will allow simplified determination of effective elements without undue experimentation or extensive structure/function knowledge. An ideal method would allow simultaneous analysis of multiple possible candidate SGEs, regardless of their mechanism of action.
BRIEF SUMMARY OF THE INVENTION
The present invention facilitates drug discovery by providing a method for identifying agents that selectively confer a desired phenotype on a target cell, comprising:
(i) transfecting subtractive cells with a library of expression vectors comprising a variegated population of coding sequences for potential synthetic genetic elements (SGEs);
(ii) isolating those SGE vectors of the SGE library that do confer the desired phenotype, or a phenotype that interferes with the detection thereof, to the subtractive cells;
(iii) transfecting target cells with the sub-population of SGE vectors isolated in step (ii); and
(iv) isolating those SGE vectors that confer the desired phenotype to the target cell.
One aspect of the subject method relates to a method for identifying agents with selective antiproliferative activity for a target cell, comprising:
(i) transfecting subtractive cells with a library of expression vectors comprising a variegated population of coding sequences for potential synthetic genetic elements (SGEs);
(ii) isolating those SGE vectors of the SGE library that are not lethal to the subtractive cells;
(iii) transfecting target cells with the non-lethal SGE vectors isolated in step (ii); and
(iv) isolating those SGE vectors that are lethal to the target cell.
In preferred embodiments, the method is carried out using target and subtractive cells that are eukaryotic cells, more preferably mammalian cells. In certain embodiments, one or both of the target and subtractive cells are human cells.
In certain embodiments, the target is a transformed cell, and the subtractive cell is an untransformed cell.
In other embodiments, the target is a cell infected with a virus, and the subtractive cell is an uninfected cell.
In preferred embodiments, the expression vectors are viral vectors, and more preferably retroviral vectors.
The SGE library can be generated from a normalized cDNA library, a subtractive cDNA library, or a combination thereof.
By random incorporation, or directional cloning, the library can be generated to include SGE having a sense oriented sequence encoding a peptide, and/or an antisense-oriented sequence encoding an antisense RNA.
Another aspect of the invention relates to formulations of the SGEs identified according to the subject method. For example, the present invention provides a synthetic oligonucleotide having a nucleotide sequence from about 12 nucleotides to all of the nucleotide sequence of an antisense RNA encoded by an SGE identified according to the subject method. In other embodiments, the invention provides an isolated peptide encoded by an SGE identified according to the subject method, or a peptidomimetic thereof.
REFERENCES:
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5174996 (1992-12-01), Weber et al.
patent: 5206352 (1993-04-01), Roninson et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264574 (1993-11-01), Carroll et al.
patent: 5283317 (1994-02-01), Saifer et al.
patent: 5580736 (1996-12-01), Brent et al.
patent: 5695941 (1997-12-01), Brent et al.
patent: 5753432 (1998-05-01), Gudkov et al.
patent: 5759776 (1998-06-01), Smith et al.
patent: 5846721 (1998-12-01), Soares et al.
patent: 5955275 (1999-09-01), Kamb
patent: WO 89/02468 (1989-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 92/07071 (1992-04-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 94/20618 (1994-09-01), None
patent: WO 95/253855 (1995-09-01), None
patent: WO 95/34680 (1995-12-01), None
patent: WO 97/27212 (1997-07-01), None
patent: WO 98/12339 (1998-03-01), None
patent: WO 98/21366 (1998-05-01), None
patent: WO 99/32618 (1999-07-01), None
patent: WO 99/47643 (1999-09-01), None
patent: WO 99/53098 (1999-10-01), None
Thomson et al. “Embryonic Stem Cell Lines Dervied from Human Blastocysts.”Science, 282: 1145 (1998).
Shamblott et al. “Derivation of luripotent stem cells from cultured human primordial germ cells.”PNAS, 95: 13726 (1998).
Palazzolo and Meyerowitz. “A family of phage cDNA cloning vectors, delta-SWAJ, allowing the amplification of RNA sequences.”Gene, 52:197-206 (1987).
Palazzolo et al. “Use of a New Strategy to Isolate and Characterize 436 Drosophila cDNA Clones Corresponding to RNAs Detected in Adult Heads but Not in Early Embryos.”Neuron, 3:527 (1989).
Palazzolo et al. “Phage Iambda cDNA cloning vectors for subtractive hybridization, fusion-protein synthesis and Cre-IoxP automatic plasmid subcloning.”Gene, 88:25 (1990).
Meissner et al. “Bacteriophage Delta cloning system for the construction of directional cDNA libraries.”PNAS, 84:4171 (1987).
Beutler et al. “Gamma-Glutamylcystein Synthetase Deficiency and Hemolytic Anemia.”Blood, 76:271 (1990).
Eglitis et al. “Gene expression in mice after high efficiency retroviral-mediated gene transfer.”Science, 230: 1395-1398 (1985).
Danos and Mulligan. “Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.”Proc. Natl. Acad. Sci. USA, 85:6460-6464 (1988).
Wilson et al. “Retrovirus-mediated transduction of adult hepatocytes.”Proc. Natl. Acad. Sci. USA, 85:3014-3018 (1988).
Armentano et al. “Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B.”Proc. Natl. Acad. Sci. USA, 87: 6141-6145 (1990).
Huber et al. “Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy”Proc. Natl. Acad. Sci. USA, 88:8039-8043 (1991).
Chowdhury et al.; “Long Term Improvement of Hypercholesterolemia After ex Vivo Gene Therapy in LDLR-Deficient Rabbits”,Science254: 1802=1805 (1990).
van Beusechem et al. “Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells.”Proc. Natl. Acad. Sci. USA, 89: 7640-7644 (1992).
Kay et al. “Hepatic Gene Therapy: Persistent Expression of Human alpha1-Antitrypsin in Mic after Direct Gene Delivery In Vivo.”Human Gene Therapy, 3:641-647 (1992).
Dai et al.; “Gene Therapy V
GPC Biotech Inc.
Halstead David P.
Ropes & Gray
Vincent Matthew P.
Wang Andrew
LandOfFree
Methods and regents for identifying synthetic genetic elements does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and regents for identifying synthetic genetic elements, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and regents for identifying synthetic genetic elements will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2845331